arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Elicio Therapeutics, Inc.

ELTX

$1.40 ▼ -0.16 (-10.26%) at close

7 Visible periods

29 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Elicio Therapeutics, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $21.4M

Dividend Yield —

Revenue Growth None

Op. Margin None

ROIC -324.1% ↗

FCF / Share $-2.41 ↗

Trailing P/E —

Price / Book 15.2x

FCF Yield —

Debt / Equity 6.11

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$2.30M

↓ -91.9% —

Net Income Profit after all expenses

$-39.57M

↑ +23.8% —

FCF / Share Free cash flow per share

$-2.41

↑ +20.7% —

Long-Term Debt Long-term obligations

$10.00M

↓ -50.1% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health

Cash Quality →

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	—	—	—	-91.9% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1248%)	883.1% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+10938%)	—	—
EPS Growth YoY (%)	39.3% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	38.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-439.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	33.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	64.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	23.8% Good ↑ Good Improving Year-over-year change in net income	-47.5% Weak ↓ Weak Declining Year-over-year change in net income	9.3% Fair ↓ Fair Declining Year-over-year change in net income	28.9% Excellent Excellent Year-over-year change in net income	31.9% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	20.7% Good ↑ Good Improving Year-over-year change in free cash flow	53.0% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-407.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	31.9% Excellent Excellent Year-over-year change in free cash flow	-20.9% Weak Weak Year-over-year change in free cash flow	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-138.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1026%)	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	-0.0% Excellent → Excellent Stable Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	—	-192.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1706%)	—	—
FCF Margin (%) (%)	—	—	—	—	-187.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.93x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.97x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.29x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-324.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-515.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-248.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-90.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-48.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	61.5% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-145.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-159.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-131.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-75.1% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-40.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-116.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	—	—	—	-88.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-691%)	-67.0% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-546%)	88.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+490%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	6.11x Weak Weak Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+919%)	-1.77x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-395%)	—	—	0.00x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-100%)	-0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-101%)	—
Interest Coverage (x)	—	—	-33.75x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	-5615.29x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—
Net Debt (USD)	$-8.56M	$2.42M	$-12.89M	$-50.49M	$-88.76M	$-33.97M	—
Debt / EBITDA (x)	-0.27x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.45x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	0.00x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.01x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	—	—	—	$0.08	$1.00	$0.20	—
Basic EPS, GAAP (USD)	$-2.58	$-4.25	$-6.96	$-1.29	$-1.93	$-5.43	—
Free Cash Flow per Share (USD)	$-2.41	$-3.04	$-6.48	$-1.28	$-1.88	$-1.55	—
Book Value per Share (USD)	$0.09	$-1.03	$1.18	$1.45	$2.72	$-5.91	—
Tangible Book Value per Share (USD)	$0.09	$-1.03	$1.18	$1.45	$2.72	$-5.91	—
Basic Weighted Avg Shares (shares)	15.31M	12.20M	5.06M	30.04M	28.24M	14.76M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$11.20M	$9.17M	$6.58M	$45.06M	$79.95M	$-65.15M	—
LT Debt (USD)	$10.00M	$20.03M	—	—	$0.00	$635.00K	—
Total Equity (USD)	$1.64M	$-11.31M	$11.37M	$43.77M	$81.51M	$-90.45M	$-18.59M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	$2.30M	$28.31M	$2.88M	—
Depreciation Expense (USD)	$204.00K	$321.00K	$382.00K	$178.00K	$91.00K	$98.00K	—
Net Income, GAAP (USD)	$-39.57M	$-51.90M	$-35.20M	$-38.81M	$-54.57M	$-80.11M	—
Operating Cash Flow (USD)	$-36.95M	$-37.07M	$-32.69M	$-38.39M	$-52.64M	$-22.89M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

Elicio Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ELTX with peers